NO992470L - 2-amidazolinyl-amino-indolforbindelser anvendelige som <alfa>-2-adreno-reseptoragonister - Google Patents

2-amidazolinyl-amino-indolforbindelser anvendelige som <alfa>-2-adreno-reseptoragonister

Info

Publication number
NO992470L
NO992470L NO992470A NO992470A NO992470L NO 992470 L NO992470 L NO 992470L NO 992470 A NO992470 A NO 992470A NO 992470 A NO992470 A NO 992470A NO 992470 L NO992470 L NO 992470L
Authority
NO
Norway
Prior art keywords
amidazolinyl
alpha
amino
compounds useful
indole compounds
Prior art date
Application number
NO992470A
Other languages
English (en)
Norwegian (no)
Other versions
NO992470D0 (no
Inventor
Raymond Todd Henry
William Lee Seibel
Russell James Sheldon
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO992470D0 publication Critical patent/NO992470D0/no
Publication of NO992470L publication Critical patent/NO992470L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO992470A 1996-11-25 1999-05-21 2-amidazolinyl-amino-indolforbindelser anvendelige som <alfa>-2-adreno-reseptoragonister NO992470L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3177796P 1996-11-25 1996-11-25
PCT/US1997/020801 WO1998023610A1 (en) 1996-11-25 1997-11-21 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists

Publications (2)

Publication Number Publication Date
NO992470D0 NO992470D0 (no) 1999-05-21
NO992470L true NO992470L (no) 1999-07-26

Family

ID=21861336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992470A NO992470L (no) 1996-11-25 1999-05-21 2-amidazolinyl-amino-indolforbindelser anvendelige som <alfa>-2-adreno-reseptoragonister

Country Status (23)

Country Link
US (2) US6162818A (he)
EP (1) EP0944621B1 (he)
JP (1) JP2001506981A (he)
KR (1) KR100395356B1 (he)
CN (1) CN1092652C (he)
AR (1) AR013875A1 (he)
AT (1) ATE275142T1 (he)
AU (1) AU735767B2 (he)
BR (1) BR9713542A (he)
CA (1) CA2271841C (he)
CO (1) CO4910149A1 (he)
CZ (1) CZ180599A3 (he)
DE (1) DE69730516T2 (he)
ES (1) ES2225998T3 (he)
HU (1) HUP9904215A3 (he)
ID (1) ID22812A (he)
IL (1) IL130024A (he)
NO (1) NO992470L (he)
PE (1) PE16299A1 (he)
SK (1) SK68399A3 (he)
TR (1) TR199901885T2 (he)
WO (1) WO1998023610A1 (he)
ZA (1) ZA9710577B (he)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
CZ180599A3 (cs) * 1996-11-25 1999-11-17 The Procter & Gamble Company 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
WO2001040183A1 (en) * 1999-12-03 2001-06-07 Alcon Universal Ltd. 1-aminoalkyl-1h-indoles for treating glaucoma
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
CN100497334C (zh) * 2002-06-24 2009-06-10 先灵公司 用作组胺h3拮抗剂的吲哚衍生物
US7795280B2 (en) 2002-11-07 2010-09-14 N.V. Organon Indoles useful in the treatment of androgen-receptor related diseases
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
CL2008000838A1 (es) * 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
JP5671459B2 (ja) * 2008-08-01 2015-02-18 アイ・セラピーズ・エル・エル・シー 血管収縮組成物および使用方法
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
CH632268A5 (de) * 1977-01-14 1982-09-30 Sandoz Ag Verfahren zur herstellung von neuen heterocyclylaminoderivaten.
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
CZ180599A3 (cs) * 1996-11-25 1999-11-17 The Procter & Gamble Company 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití

Also Published As

Publication number Publication date
EP0944621A1 (en) 1999-09-29
ATE275142T1 (de) 2004-09-15
WO1998023610A1 (en) 1998-06-04
KR100395356B1 (ko) 2003-08-21
AU5438098A (en) 1998-06-22
HUP9904215A2 (hu) 2000-06-28
SK68399A3 (en) 2000-07-11
ZA9710577B (en) 1998-06-25
CO4910149A1 (es) 2000-04-24
CN1238771A (zh) 1999-12-15
ID22812A (id) 1999-12-09
ES2225998T3 (es) 2005-03-16
DE69730516D1 (de) 2004-10-07
CN1092652C (zh) 2002-10-16
KR20000069088A (ko) 2000-11-25
CZ180599A3 (cs) 1999-11-17
EP0944621B1 (en) 2004-09-01
DE69730516T2 (de) 2005-09-01
HUP9904215A3 (en) 2002-01-28
JP2001506981A (ja) 2001-05-29
AU735767B2 (en) 2001-07-12
IL130024A (he) 2002-12-01
AR013875A1 (es) 2001-01-31
CA2271841A1 (en) 1998-06-04
US6395764B1 (en) 2002-05-28
BR9713542A (pt) 2000-01-25
CA2271841C (en) 2003-07-08
TR199901885T2 (xx) 1999-10-21
IL130024A0 (en) 2000-02-29
US6162818A (en) 2000-12-19
NO992470D0 (no) 1999-05-21
PE16299A1 (es) 1999-03-12

Similar Documents

Publication Publication Date Title
NO992470D0 (no) 2-amidazolinyl-amino-indolforbindelser anvendelige som &lt;alfa&gt;-2-adreno-reseptoragonister
NO20010603D0 (no) 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20001141D0 (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
DK0945132T3 (da) Ibuprofen-præparat
NO20001142L (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
NO20001139D0 (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
FI4209U1 (fi) Uusia yhdisteitä
NO975453D0 (no) Kjemisk sammensetning
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
NO992498D0 (no) Guanidinylheterocykelforbindelser anvendelige som &lt;alfa&gt;-2 adrenoceptoragonister
DE69700310D1 (de) Rostschutzzusammensetzung
EE9800430A (et) Uued ühendid
NO20013013L (no) &lt;alfa&gt;v&lt;beta&gt;6-integrininhibitorer
ID17561A (id) Komposisi untuk pemakaian luar
NO992500L (no) 2-imidazolinylaminobenzoksazolforbindelser anvendelige som &lt;alfa&gt;-2 adrenoceptoragonister
NO975454D0 (no) Kjemisk sammensetning
DK0934264T3 (da) Pyrrolidinyl- og pyrrolinylethylaminforbindelser som kappa-agonister
NO20011664D0 (no) Sammensetning med höy renhet omfattende (7&lt;alfa&gt;, 17&lt;alfa&gt;)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on
NO995030D0 (no) 5-(2-imidazolinylamino)benzimidazolforbindelser nyttige som &lt;alfa&gt;-2-adrenoseptoragonister
NO992502D0 (no) 2-Imidazolinylaminoindazolforbindelser nyttige som &lt;alfa&gt;-2 adrenerge reseptoragonister
NO992503L (no) Guanidinylamino heterocykelforbindelser nyttige som &lt;alfa&gt;-2 adrenerge reseptoragonister
EE9900012A (et) Uudsed ühendid
NO20010280D0 (no) &lt;Alfa&gt;-aminosyrefenylesterderivater
SE9804211D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application